Skip to content

Test observation of human body test on the treatment of chloasma with Lutai Danshen Baishao Granules, a Chinese medicine compound health product

Test observation of human body test on the treatment of chloasma with Lutai Danshen Baishao Granules, a Chinese medicine compound health product

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005457
Enrollment
Unknown
Registered
2021-12-28
Start date
2021-12-27
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Interventions

Sponsors

CONO TECHNOLOGY GROUP
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Female aged 18-65 years old. ? Stable chloasma, light brown to dark brown on the face, well-defined patches, usually symmetrically distributed, without inflammatory manifestations and scales. ? No obvious symptoms. ? Sign the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: ? Melasma caused by disease. ? Women who are planning to become pregnant, pregnant or breast-feeding. ? People with allergies and allergies to this health food. ? Subjects with severe diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, endocrine diseases, and mental illness. ? Alcoholics (alcohol content <15g, alcohol content = alcohol consumption × alcohol concentration × 0.8) or smokers. ? Those who have taken or topical anti-freckle and whitening products within 4 weeks before the start of the food test, or have been treated with laser or fruit acid, will affect the judgment of the results.

Design outcomes

Primary

MeasureTime frame
MASI;Heart rate, heart rhythm, blood pressure;

Countries

P.R.China

Contacts

Public ContactWang Linyuan
wanglinyuan110@vip.163.com13381002202

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026